Liver cancer is the third leading cause of cancer mortality worldwide. Currently, therapeutic options are limited. Innovative research on the pathogenesis of disease at the molecular and cellular levels is urgently needed.
This project will develop and employ state-of-the-art genetic mouse models and cutting-edge molecular technologies to study the fate, function and molecular alterations in distinct liver epithelial subsets during liver cancer initiation and progression.
We will also develop PDXs (patient-derived xenograft) and PDO (patient-derived organoids) as preclinical models to facilitate the translation of novel discoveries to clinical practice. Moreover, we will collaborate with local and international clinician scientists to explore the potential of novel biomarkers and therapeutic targets identified from this project for the diagnosis, prognosis and treatment of liver cancer.
